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What Are We Waiting For?*Mackram F. Eleid, MD, Patricia A. Pellikka, MD“Observe due measure, for right timing is in
all things the most important factor.”
—Hesiod, Works and Days (c. 700 BC) (1)C alciﬁc degenerative aortic stenosis (AS)is a common cause of acquired valvularheart disease affecting predominantly older
adults. Over time, accumulation of valve calciﬁca-
tion restricts leaﬂet motion, leading to progressive
outﬂow obstruction, afterload mismatch, and symp-
toms. Traditionally, the asymptomatic phase of
severe AS (stage C) has been associated with a low
risk of sudden death (2–4), such that close observa-
tion for the development of symptoms is recommen-
ded before proceeding with aortic valve replacement
(AVR) (5).SEE PAGE 2827In this issue of the Journal, Taniguchi et al.
(6) report 5-year outcomes of the CURRENT AS
(Contemporary Outcomes after Surgery and Medical
Treatment in Patients with Severe Aortic Stenosis)
registry of 1,808 patients with asymptomatic severe
AS who were initially treated either conservatively
(n ¼ 1,517) or with initial AVR (n ¼ 291). The authors
found a higher rate of mortality (26.4% vs. 15.4%;
p ¼ 0.009) and hospitalizations for heart failure
(19.9% vs. 3.8%; p < 0.001) at 5 years of follow-up
in patients who were managed conservatively com-
pared with those undergoing initial AVR. These
data seemingly conﬂict with recommendations of*Editorials published in the Journal of the American College of Cardiology
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this paper to disclose.watchful waiting for the development of symptoms,
and beg the question, “What are we waiting for?”
in the patient with asymptomatic severe AS.
One of the unique strengths of the dataset pre-
sented by Taniguchi et al. (6) is the large number of
patients with severe AS who were initially managed
conservatively. Most contemporary cohorts have a
higher referral rate for AVR, leaving small numbers of
conservatively managed patients and limiting statis-
tical comparisons. Additionally, the authors should
be commended for including hospitalizations for
heart failure as part of the primary endpoint, because
the development of congestive heart failure in AS
represents a more advanced stage of disease that
should be avoided. Interestingly, AVR mortality
was higher in patients who underwent intervention
after symptom onset compared with asymptomatic
patients, further supporting the notion that earlier
surgery may be beneﬁcial. During a median follow-up
of 2 years, 41% of patients initially managed conser-
vatively required AVR, which is in keeping with
previous estimates that progression to required
intervention within 5 years of developing severe AS is
almost inevitable.
Why might asymptomatic AS be a different prob-
lem now than was observed only 10 to 20 years ago?
Several potential reasons for this may exist. The rate
of sudden death in this study was slightly higher than
previously reported (1.5% per year compared with
earlier estimates of 1.0% per year) (2,3). Today, AS
patients are an elderly population, often with multi-
ple comorbidities, potentially leaving them more
vulnerable to the hemodynamic derangements asso-
ciated with severe AS. Furthermore, AVR mortality is
lower now than it used to be and can be accurately
estimated using the Society for Thoracic Surgeons
risk calculator (7).
Although the study methods were robust (6),
asymptomatic status was not conﬁrmed by treadmill
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2843exercise test, therefore leaving the possibility
of undetected or unrecognized symptoms in some
patients due to sedentary lifestyle. In fact, the
updated American College of Cardiology/American
Heart Association guidelines provide a class IIa
recommendation for AVR in asymptomatic patients
with severe AS (stage C1) who have decreased
exercise tolerance on treadmill testing (5).
Furthermore, as the authors point out, monitoring
for symptoms can be an imprecise undertaking
and some patients will inevitably be lost to follow-
up using this strategy. Although a retrospective
study, the authors appropriately used a propensity
score-matched cohort to minimize selection bias
in comparing outcomes in patients managed
conservatively versus with initial AVR. Despite
these measures, the population in this Japanese-
based study may have unique features compared
with Western populations that limit the generaliz-
ability of the study results. The high prevalence
of obesity in the United States, even in patientswith severe AS (8), for instance, is not represented
in this Japanese cohort with mean body mass index
of 22 kg/m2, which potentially could affect AVR
outcomes.
Appropriate timing of the intervention for each
individual patient is essential to balance the nat-
ural risk of severe AS with the risk of AVR. This
study sheds new light on optimal management
strategies in asymptomatic severe AS and raises
many more important questions. Ultimately, how-
ever, we await a randomized controlled trial of
patients with asymptomatic severe AS to address
the question of whether early AVR is preferable to
a strategy in which AVR is deferred until symp-
toms develop.
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